We at CFIF often highlight the clear and present danger that drug price control schemes pose to American…
CFIF on Twitter CFIF on YouTube
New Lung Cancer Breakthrough Illustrates the Potential Peril of Drug Price Controls

We at CFIF often highlight the clear and present danger that drug price control schemes pose to American consumers, who benefit from our private pharmaceutical sector that leads the world - by far - in innovation.  A new lung cancer treatment breakthrough in the form of Amgen's Lumakras illustrates that interrelationship.

Simply put, Lumakras reduced the risk of progression by 34% compared to chemotherapy in patents with advanced lung cancer, which is particularly welcome considering lung cancer's especially low survival rate (18.6% over five years, and just 5% for advanced forms).  The breakthrough required years of research and enormous amounts of investment, however, which The Wall Street Journal notes makes Lumakras the type of innovation put at risk by new drug price controls…[more]

September 22, 2022 • 05:06 PM

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
Jester's Courtroom Legal tales stranger than stranger than fiction: Ridiculous and sometimes funny lawsuits plaguing our courts
US Should Vaccinate Its Own Before Sharing Vaccines Print
By Betsy McCaughey
Wednesday, January 27 2021
There are powerful reasons to oppose COVAX's vaccine-sharing principles.

On Thursday, Anthony Fauci informed the World Health Organization that the Biden administration will participate in WHO's vaccine-sharing project. That reverses President Donald Trump's "America First" approach. Fauci says the goal is to ensure "equitable access" to vaccines for all countries in the world, rich and poor alike. 

Americans scrambling to get vaccinated have a right to know how sharing doses with poor countries will affect their own ability to get vaccinated. 

Biden is coming under pressure from the public health community to share the vaccine supply the U.S. has prepurchased before all Americans who want shots receive them. 

The vaccine sharing project, with the acronym COVAX, raises money to buy vaccines for poor countries and asks the wealthier countries to donate actual doses. The COVAX dose-sharing principles, released Dec. 18, are causing controversy in France, England, Canada and other countries struggling to get their own populations vaccinated. COVAX wants countries to share their doses as they receive them, rather than waiting to see what's leftover. So far, Norway has agreed. 

WHO Director-General Tedros Adhanom Ghebreyesus says it's unfair for younger, healthy adults in countries like the U.S. to get injections before the frail and elderly in poor countries. He calls it a "catastrophic moral failure."

Similarly, Kate Elder of Doctors Without Borders objects "if a healthy 20-year-old in New Jersey is getting vaccinated before a front line health care worker in South Sudan." 

Bruce Aylward, a WHO adviser, claims it's unacceptable for a country to vaccinate its entire population before offering doses to the highest risk inhabitants of poorer countries. 

Duke University public health experts also argue that high-risk groups in poor countries should get the vaccine before the U.S. public. A report from the Duke Global Health Innovation Center complains that wealthy countries are monopolizing the initial supply. 

Thursday's White House statement on vaccine sharing says the U.S. will comply once there is "sufficient" supply here. What does "sufficient" mean? When just those at highest risk are vaccinated, as globalists propose, or when shots have been offered to all Americans? The public needs a clear answer to that question. 

There are powerful reasons to oppose COVAX's vaccine-sharing principles. 

First, U.S. taxpayers poured billions into Operation Warp Speed to develop the vaccines with the understanding they'd get a large share of initial production. When Trump refused to join COVAX, The New York Times slammed the decision as "vaccine nationalism," but Americans desperate to get vaccinated are unlikely to be worried about political correctness. 

Second, the U.S. is striving to reach herd immunity by summer, which scientists predict will require about 70% of the population to be vaccinated. Diverting some of the vaccine supply to COVAX would endanger that goal. 

On Monday, the International Chamber of Commerce joined the call for equitable distribution of vaccines, arguing that helping poor nations will benefit the economies of wealthy ones. True in the long run, but vaccinating a quarter of the population of every country, as COVAX proposes, would necessitate the US and other developed countries giving up a return to normal this year. 

Third, as new virus variants emerge, vaccination becomes even more a race against the clock. Otherwise a variant could appear that is not susceptible to the vaccine. Moderna announced Monday that its vaccine is somewhat less effective against the recently identified South African variant. People may need yearly boosters against emerging strains. 

In the last two weeks, both the European Union and the U.S. have been hit with unexpected news about manufacturing setbacks. Monday the European Union actually threatened to ban Astra-Zeneca from exporting any doses until it meets its contractual obligations. The EU is putting its own people first. 

That's a lesson for America. Decisions about vaccine sharing should not be left to public health "experts" whose globalist views are now ascendant in Washington, D.C. Helping the world is important, but America needs to take care of its own first. 


Betsy McCaughey is a former lieutenant governor of New York and author of "The Next Pandemic," available at Amazon.com. 

COPYRIGHT 2021 CREATORS.COM

Quiz Question   
Which one of the following U.S. Presidents signed the executive order establishing the Federal Emergency Management Agency (FEMA)?
More Questions
Notable Quote   
 
"Now they tell us. We're referring to the Congressional Budget Office, which finally rolled in Monday with its cost estimate for President Biden's unilateral student-loan write-down: $420 billion. ...The cost of Mr. Biden's unilateral extension of the moratorium on student loan payments for another three months through December will be $20 billion. But that's a bargain compared to the $400 billion…[more]
 
 
—The Wall Street Journal Editorial Board
— The Wall Street Journal Editorial Board
 
Liberty Poll   

Choosing from the list below, what issue is currently most important to you heading into the mid-term elections?